Ceftriaxone versus cefepime or carbapenems for definitive treatment of low-risk AmpC-Harboring Enterobacterales bloodstream infections in hospitalized adults: A retrospective cohort study
Authors:
- 13 October 2024
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 111 (1) , 116557
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of CautionClinical Infectious Diseases, 2024
- Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC EnterobacteralesAntimicrobial Agents and Chemotherapy, 2023
- Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)Open Forum Infectious Diseases, 2021
- Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative reviewInternational Journal of Antimicrobial Agents, 2020
- Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream InfectionsClinical Infectious Diseases, 2018
- Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamaseJournal of Antimicrobial Chemotherapy, 2018